User:Ely.yatun/Piroxicam

Pharmacogenomics
Piroxicam is metabolized by CYP2C9, so any deviations from the normal activity of the gene can cause an increase in toxicity in patients. CPIC Guideline classify this as an actionable pharmacogenetic interaction meaning that it is recommended to do a genetic test before initiating treatment. Based on the activity score that the genetic found we can then make decision on the treatment.

Activity score of 2 (normal metabolizer)

 * Use regular dose.
 * Use regular duration of treatment.
 * Low chance of adverse effects.

Activity score of 1.5 (intermediate metabolizer)

 * Use regular dose.
 * Use regular duration of treatment.
 * no significant increase in side effects.

Activity score of 1 (intermediate metabolizer)

 * Avoid the use of Piroxicam.
 * Increased chance of significant side effects.

Activity score of 0 - 0.5 (poor metabolizer)

 * Avoid the use of Piroxicam.
 * Increased chance of significant side effects.